Last reviewed · How we verify
NCT06120127: IMPROVE
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
Phase 2 trial testing SBRT in Radiotherapy in 80 participants. Status unknown.
25 September 2025
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 25 September 2023 |
| Primary completion | 25 September 2025 |
| Estimated completion | 25 September 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- SBRT — full drug profile →
- Chemotherapy (chemotherapy) — full drug profile →
- PD-1 antibody — full drug profile →
Conditions studied
- Radiotherapy — all drugs for Radiotherapy →
- Immunotherapy — all drugs for Immunotherapy →
- Liver Metastases — all drugs for Liver Metastases →
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
Fudan University
Who can join
18 and older, any sex, with Radiotherapy or Immunotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a randomized controlled phase II trial to evaluate the efficacy of the combination of stereotactic body radiation therapy (SBRT) and immunotherapy with postoperative chemotherapy in colorectal cancer liver metastasis (CRLM) patients with high risk of locally recurrence. Researchers will compare the combination therapy with the postoperative chemotherapy alone to see if postoperative chemotherapy plus SBRT and immunotherapy can further reduce the risk of recurrence and metastasis after surgery.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The dual nature of immunotherapy in female reproductive disorders: immune homeostasis and clinical challenges.
Abulajiang Y, Wu Y, He Y. · · 2025 · cited 1× · PMID 41112246 · DOI 10.3389/fimmu.2025.1658681 -
Emerging Applications of Stereotactic Ablative Radiotherapy in Oligometastatic Colorectal Cancer.
Al-Sattar H, Okondo E, Jaafari AM, Sood I, et al · · 2025 · PMID 41226343 · DOI 10.3390/ijms262110302
Verify or expand the search:
- PubMed search for NCT06120127
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SBRT
Trials testing the same drug.
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
- NCT07451795 — SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC · Phase 2 · recruiting
- NCT07410234 — Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity · Phase 2 · not yet recruiting
Other recruiting trials for Radiotherapy
Currently open trials in the same condition.
- NCT07493928 — HPV After chemoRadioTherapy · recruiting
- NCT07378631 — Association Between Clinical Subtypes and Prognosis in Radiation Rectal Injury · recruiting
- NCT07339488 — Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal · Phase 2 · active not recruiting
- NCT07469267 — Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases · NA · recruiting
- NCT07447570 — Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC · Phase 2 · recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06120127 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 7 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06120127.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing